realMIND: Observational Study on Safety and Effectiveness of Tafasitamab in Combination With Lenalidomide in Patients With Relapsed or Refractory DLBCL
Condition(s):Diffuse Large B-cell LymphomaLast Updated:March 22, 2024Recruiting
Include Studies Not Open or Pending
Condition(s):Diffuse Large B-cell LymphomaLast Updated:March 22, 2024Recruiting
Condition(s):DLBCLLast Updated:September 23, 2022Recruiting
Condition(s):Lymphoma, Large B-Cell, Diffuse; Neoplasms by Histologic TypeLast Updated:March 7, 2022Not yet recruiting
Condition(s):Relapsed or Refractory B-cell LymphomaLast Updated:November 7, 2023Not yet recruiting
Condition(s):Relapsed Diffuse Large B-cell Lymphoma; Refractory Diffuse Large B-Cell LymphomaLast Updated:October 12, 2023Recruiting
Condition(s):Relapsed or Refractory DLBCL Patients With Either CD19 or CD20 PositiveLast Updated:January 2, 2020Recruiting
Condition(s):Recurrent B-Cell Non-Hodgkin Lymphoma; Recurrent Diffuse Large B-Cell Lymphoma; Recurrent Hodgkin Lymphoma; Refractory B-Cell Non-Hodgkin Lymphoma; Refractory Diffuse Large B-Cell Lymphoma; Refractory Hodgkin LymphomaLast Updated:March 6, 2024Recruiting
Condition(s):Diffuse Large B Cell Lymphoma,DLBCLLast Updated:January 19, 2024Recruiting
Condition(s):Relapsed or Refractory DLBCLLast Updated:April 7, 2022Not yet recruiting
Condition(s):Non-Hodgkin Lymphoma; Relapsed/Refractory Diffuse Large B-cell LymphomaLast Updated:January 9, 2024Recruiting
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.